>
Cellmid logo

CDY - Cellmid Share Price

A$0.061 -0.0  -3.2%

Last Trade - 15/10/21

Sector
Consumer Defensives
Size
Micro Cap
Market Cap £6.66m
Enterprise Value £3.79m
Revenue £3.15m
Position in Universe 1730th / 1953
Bullish
Bearish
Unlock CDY Revenue
Momentum
Relative Strength (%)
1m +20.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -54.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2016 2017 2018 2019 2020 2021 2022E 2023E CAGR / Avg
3.39 4.72 5.76 7.47 7.34 5.82 30.3 36.1 +11.4%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2021, CellmidLimited revenues decreased 21% to A$5.8M. Net loss beforeextraordinary items decreased 13% to A$3.8M. Revenuesreflect Advangen Japan segment decrease of 27% to A$4.3M,Cellmid Australia segment decrease of 23% to A$778K, Japansegment decrease of 27% to A$4.3M. Lower net loss reflectsAdvangen Australia segment loss decrease of 39% to A$910K,Advangen USA segment loss decrease of 33% to A$570K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CDY Revenue Unlock CDY Revenue

Net Income

CDY Net Income Unlock CDY Revenue

Normalised EPS

CDY Normalised EPS Unlock CDY Revenue

PE Ratio Range

CDY PE Ratio Range Unlock CDY Revenue

Dividend Yield Range

CDY Dividend Yield Range Unlock CDY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CDY EPS Forecasts Unlock CDY Revenue
Profile Summary

Cellmid Limited is an Australia-based health and beauty-tech business company. The Company is specialized in developing anti-aging solutions. The Company operates through two segments: Diagnostics and Consumer Health. The Company is engaged in the research and development of diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine. It is also engaged in the development and sale of over the counter (OTC) and cosmetic products for hair loss and anti-aging hair care through its FGF5 inhibitor technology. It has developed a range of products under the evolis, evolis Professional, Lexilis Hybrid, Jo-JuRED and Lexilis BLACK brands.

Directors
Last Annual June 30th, 2021
Last Interim June 30th, 2021
Incorporated October 8, 2004
Public Since December 9, 2005
No. of Shareholders: 2,280
No. of Employees: n/a
Sector Consumer Defensives
Industry Personal & Household Products & Services
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 201,386,655
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CDY Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CDY
Upcoming Events for CDY
Friday 22nd October, 2021
Cellmid Ltd Ordinary Shareholders Meeting
Tuesday 30th November, 2021 Estimate
Cellmid Ltd Annual Shareholders Meeting
Tuesday 15th February, 2022 Estimate
Half Year 2022 Cellmid Ltd Earnings Release
Frequently Asked Questions for Cellmid
What is the Cellmid share price?

As of 15/10/21, shares in Cellmid are trading at A$0.061, giving the company a market capitalisation of £6.66m. This share price information is delayed by 15 minutes.

How has the Cellmid share price performed this year?

Shares in Cellmid are currently trading at A$0.061 and the price has moved by -37.58% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cellmid price has moved by -47.83% over the past year.

What are the analyst and broker recommendations for Cellmid?

Of the analysts with advisory recommendations for Cellmid, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cellmid is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Cellmid next release its financial results?

Cellmid is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Cellmid dividend yield?

Cellmid does not currently pay a dividend.

Does Cellmid pay a dividend?

Cellmid does not currently pay a dividend.

When does Cellmid next pay dividends?

Cellmid does not currently pay a dividend.

How do I buy Cellmid shares?

To buy shares in Cellmid you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cellmid?

Shares in Cellmid are currently trading at A$0.061, giving the company a market capitalisation of £6.66m.

Where are Cellmid shares listed? Where are Cellmid shares listed?

Here are the trading details for Cellmid:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: CDY
What kind of share is Cellmid?

Based on an overall assessment of its quality, value and momentum, Cellmid is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cellmid share price forecast 2021?

Shares in Cellmid are currently priced at A$0.061. At that level they are trading at 1.64% discount to the analyst consensus target price of 0.00.

How can I tell whether the Cellmid share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cellmid. Over the past six months, the relative strength of its shares against the market has been -20.21%. At the current price of A$0.061, shares in Cellmid are trading at -14.58% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cellmid PE Ratio?

We were not able to find PE ratio data for Cellmid.

Who are the key directors of Cellmid?

Cellmid's management team is headed by:

Maria Halasz - CEO
Bruce Gordon - NID
Martin Cross - NED
Dennis Eck - NED
Lee Tamplin - SEC
Dominic Burg - COO
Sarah Eck-Thompson - DRC
Who are the major shareholders of Cellmid?

Here are the top five shareholders of Cellmid based on the size of their shareholding:

Eck (Dennis) Individual Investor
Percentage owned: 9.68% (18.1m shares)
P&M Maguire Super Pty. Ltd. Corporation
Percentage owned: 4.7% (8.80m shares)
Moore Family Super Fund Pty. Ltd. Corporation
Percentage owned: 4.5% (8.43m shares)
Halasz (Maria Julianna) Individual Investor
Percentage owned: 2.67% (5.00m shares)
IQ Global Asset Partners Pty. Ltd. Corporation
Percentage owned: 2.38% (4.46m shares)
Similar to CDY
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.